Key takeaways
Atripla (efavirenz/emtricitabine/tenofovir) and Triumeq (abacavir/dolutegravir/lamivudine) are both single-tablet regimens used to treat HIV, but they have some key differences. Atripla contains a non-nucleoside reverse transcriptase inhibitor (NNRTI) and two nucleoside reverse transcriptase inhibitors (NRTIs), while Triumeq includes an integrase inhibitor and two NRTIs. Atripla must be taken on an empty stomach, preferably at bedtime to avoid side effects like dizziness, whereas Triumeq can be taken with or without food. Triumeq requires a genetic test before starting to check for a risk of serious allergic reactions, which is not needed for Atripla. Additionally, Atripla is available as a generic, making it potentially more affordable, while Triumeq is not. Both medications have significant side effects and interactions, but Atripla is particularly noted for its potential to cause kidney and bone problems, while Triumeq has a higher risk of severe allergic reactions and liver issues.
